Treatment of metastatic breast cancer: second line and beyond
Authors:
- 21 October 2010
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 22 (5) , 1000-1010
Abstract
Increasing use of standard chemotherapy, especially anthracycline- and taxane-based therapies, in early-stage breast cancer has led to a corresponding increase in heavily pretreated and/or treatment-resistant cases of metastatic breast cancer (MBC). Thus, second and later lines of MBC therapy frequently involve the clinically challenging picture of progressive disease and limited treatment options. While several prognostic factors have been identified to aid treatment selection in MBC patients, treatment is palliative and aimed at prolonging survival, controlling symptoms, and maximizing patients' quality of life. No globally accepted standard exists for meeting these goals, and treatment patterns vary according to region. The list of available agents for the treatment of MBC is increasing with newer chemotherapeutic agents and molecular-targeted therapies. Within recent years, several single-agent and combination chemotherapy regimens have been shown to improve progression-free survival and reduce symptoms of disease in clinical studies in patients with resistant and/or heavily pretreated MBC. However, at present, the demonstrated benefits of these medical interventions have usually not included extension of overall survival times. It is hoped that in the near future, ongoing refinements to treatment approaches used in second-line settings and beyond will allow meaningful improvements in symptom control and survival in MBC.Keywords
This publication has 57 references indexed in Scilit:
- Metastatic Breast Cancer: The Treatment ChallengeClinical Breast Cancer, 2008
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007
- European Perspective on the Costs and Cost-Effectiveness of Cancer TherapiesJournal of Clinical Oncology, 2007
- Does Reimbursement Influence Chemotherapy Treatment For Cancer Patients?Health Affairs, 2006
- Extending Survival with Chemotherapy in Metastatic Breast CancerThe Oncologist, 2005
- Assessment of the Current Medicare Reimbursement System for Breast Cancer OperationsAnnals of Surgical Oncology, 2004
- Facts and Controversies in Systemic Treatment of Metastatic Breast CancerThe Oncologist, 2004
- Goals and Objectives in the Management of Metastatic Breast CancerThe Oncologist, 2003
- Is breast cancer survival improving?Cancer, 2003
- Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal womenCancer, 2003